• S&P 500: 1,339.99
  • Change: -0.88%
$3.21 -0.09 (-2.73%)
2/10/2012 2:54 PM

Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Current Price $3.21 Mkt Cap $223.75M
Open $3.26 P/E Ratio 0.00
Prev. Close $3.30 Div. (Yield) N/A (N/A)
Daily Range $3.16 - $3.30 Volume 1,334,156
52-Wk Range $2.27 - $5.55 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think KERX will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

359 Outperform
28 Underperform
 

All-Star Players

61 Outperform
8 Underperform
 

Wall Street

7 Outperform
1 Underperform
 

Top KERX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.29)
Submitted September 06, 2011

Keryx is another biotech which has struggled recently despite an absence of negative developments specific to the company. The company has already reported positive phase III efficacy data for kidney failure drug Zerenex and is only awaiting results… More

2 Comments | Reply | Report this Post

supez2004 (52.74)
Submitted March 03, 2008

Phase 3 for sulodexide unlikely to impress ...

1 Comment | Reply | Report this Post
KERX VS S&P 500 (SPY)

Fools bullish on KERX are also bullish on:

Fools bearish on KERX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about KERX.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 10/14/2011 1:51:20 PM : Outperform Start Price: $2.79 KERX Score: +5.03

biotech

Report this Post Add Comment | Reply | Permalink

Recs

4
Member Avatar zzlangerhans (99.29) Submitted: 9/6/2011 5:16:56 PM : Outperform Start Price: $3.79 KERX Score: -31.43

Keryx is another biotech which has struggled recently despite an absence of negative developments specific to the company. The company has already reported positive phase III efficacy data for kidney failure drug Zerenex and is only awaiting results of a phase III safety trial in June 2012 before proceeding with an NDA. Meanwhile, phase III efficacy data for anti-neoplastic agent perifosine in colorectal cancer may be available as early as Q4 2011, although I suspect that timeframe may be pushed back. The trial recently passed the final interim futility analysis. Like all speculative stocks, Keryx could potentially drop much further in a broad decline but is definitely one to watch for a rebound.

Report this Post 2 Comments | Reply | Permalink

Recs

1
Member Avatar StockDocStan (< 20) Submitted: 9/2/2011 2:32:53 PM : Outperform Start Price: $3.86 KERX Score: -30.76

I cannot resist the potential, so I am parking my money in a good basket of small cap biotech picks. This is the sector to be in for the next 5 years in a big, big way. Only picking the stocks in this sector with the brightest potential.

Report this Post Add Comment | Reply | Permalink
View All 66 Pitches »

Leaderboard

Find the members with the highest scoring picks in KERX.

Score Leader

AltaVest

AltaVest (< 20) Score: +171.17

The Score Leader is the player with the highest score across all their picks in KERX.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
MTF108 56.11 8/28/2006 Underperform 3W $12.05 -73.36% +10.29% +83.65 0 Comment
Made4WallStreet 68.87 12/29/2006 Underperform 1Y $13.39 -76.03% +0.24% +76.27 0 Comment
Darbhanga 81.47 5/5/2010 Underperform 3M $6.08 -47.19% +14.32% +61.51 0 Comment
supez2004 52.74 3/3/2008 Underperform NS $5.75 -44.17% +4.99% +49.16 2 Comments
zokes10 96.96 4/13/2010 Underperform NS $4.82 -33.40% +11.85% +45.26 0 Comment
zokes101 99.75 4/13/2010 Underperform NS $4.79 -32.99% +12.00% +44.98 0 Comment
CHICAGOREALTOR < 20 4/14/2010 Underperform 5Y $4.65 -30.97% +11.52% +42.49 0 Comment
vbaci 99.42 8/24/2010 Underperform 5Y $3.68 -12.77% +26.46% +39.23 0 Comment
Korodas < 20 9/1/2010 Underperform NS $3.72 -13.71% +23.83% +37.54 0 Comment
JGus 29.03 4/20/2010 Underperform 5Y $4.25 -24.47% +10.99% +35.46 0 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackOppenheimer 79.38 5/17/2011 Outperform NS $4.92 -34.76% +1.08% -35.84 0 Comment
trackmlvcapital 78.07 5/6/2011 Outperform NS $4.66 -31.12% -0.60% -30.51 0 Comment
TrackJMP 84.89 3/16/2011 Outperform NS $4.40 -27.05% +4.45% -31.50 0 Comment
TrackLadenburg 78.30 5/11/2010 Outperform NS $6.03 -46.77% +14.79% -61.56 0 Comment
TrackRodmanRen < 20 3/2/2010 Outperform NS $2.64 +21.59% +19.36% +2.23 0 Comment
TrackRothCapital < 20 2/25/2010 Outperform NS $2.40 +104.17% +23.95% +80.22 5/3/2011 @ $4.90 0 Comment
TrackBearStearns 94.72 9/17/2009 Underperform NS $1.88 +70.74% +27.02% -43.73 0 Comment
TrackBreanMurray 66.76 9/16/2009 Outperform NS $1.88 +70.74% +27.02% +43.73 0 Comment
TrackPZK < 20 9/16/2009 Outperform NS $1.88 +70.74% +27.02% +43.73 0 Comment
TrackRodmanRen < 20 6/11/2007 Outperform NS $10.65 -92.96% -14.22% -78.73 3/10/2008 @ $0.75 0 Comment
TrackBofASec 96.90 11/2/2006 Outperform NS $13.51 -95.11% -5.05% -90.06 3/11/2008 @ $0.66 0 Comment

Featured Broker Partners